Scribd Logo
Upload

Welcome to Scribd!

  • 223 views

    Measurement of Bioavailability

    Uploaded by

    Hritik Chaubey
    1. This document discusses pharmacokinetic methods for determining the bioavailability of drugs in humans based on the relationship between drug concentration in plasma over time. 2. Key pharmacokinetic methods discussed include plasma level studies, urinary excretion studies, and multiple dose studies to determine parameters like Cmax, Tmax, AUC, half-life, and extent of absorption. 3. Parameters from single dose and multiple dose studies can be used to calculate the extent of bioavailability and compare rates of absorption between doses.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Measurement of Bioavailability

    Uploaded by

    Hritik Chaubey
    223 views5 pages
    1. This document discusses pharmacokinetic methods for determining the bioavailability of drugs in humans based on the relationship between drug concentration in plasma over time. 2. Key pharmacokinetic methods discussed include plasma level studies, urinary excretion studies, and multiple dose studies to determine parameters like Cmax, Tmax, AUC, half-life, and extent of absorption. 3. Parameters from single dose and multiple dose studies can be used to calculate the extent of bioavailability and compare rates of absorption between doses.

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    1. This document discusses pharmacokinetic methods for determining the bioavailability of drugs in humans based on the relationship between drug concentration in plasma over time. 2. Key pharmacokinetic methods discussed include plasma level studies, urinary excretion studies, and multiple dose studies to determine parameters like Cmax, Tmax, AUC, half-life, and extent of absorption. 3. Parameters from single dose and multiple dose studies can be used to calculate the extent of bioavailability and compare rates of absorption between doses.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    223 views5 pages

    Measurement of Bioavailability

    Uploaded by

    Hritik Chaubey
    1. This document discusses pharmacokinetic methods for determining the bioavailability of drugs in humans based on the relationship between drug concentration in plasma over time. 2. Key pharmacokinetic methods discussed include plasma level studies, urinary excretion studies, and multiple dose studies to determine parameters like Cmax, Tmax, AUC, half-life, and extent of absorption. 3. Parameters from single dose and multiple dose studies can be used to calculate the extent of bioavailability and compare rates of absorption between doses.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 5

    io bhomaubsPhomorokinthi

    Mtaxument o ovailabi Dr. Parjanya Shukla


    &
    Dr. M. P. Stngh Clases
    Phoma cokinahc Mohods Phamatodynamit Mahods
    basd on Ki anumpkon thot Hura Mehod nvolves dirt maakurmnt
    ts a divet alakiomshib b/w o drug effack on a (haho)
    Ks cont. d duq in plasma & hysioJogrteal pro ws as a

    COm. drug af aik achon uncHond Hm.

    ) Plasma Laval- kimu s'udbius 4) Aculs Phomotologita uspomse.


    () Urinovy exca Hon Shudizs )Therapuhc xsponse
    Khamacokinehkc Mahods-

    (1 Plasmo avaltimg Shudias-


    Mo (ommon foY kuman bioavaliabilty sfudies

    Hood i baud on Ki Mumbion has

    Ru o dirat ulahonshib bahw.en K tonuntrakon


    drug h blood/ pJama and cmun frahon
    drila a Ke i t od achon
    In DoAsStudy
    Wih &inq dose sBudy
    By-Dr.Mahundra haBap Sihgh
    a sing doks ia adminiutarsd
    blood Aomplus au drown a spauie imu intenvals
    and
    and onalyza d or drug Content.

    A A grah is Construtad ahowing i conunraion o


    drug i'n blood a spauit Hmes Rsambl wOTA take
    ioavalabilily (hi salt ond oxtent of drug ahtorphon)
    aname d by Dr. Parjanya Shukla
    I genunally
    Dr. M.P. Singh Clases
    datermining ru poram skrs
    ()max Prok Plasmo Conunfrahon)
    Max imum canuntvaion d tho dru9 ohtaina d oftun

    K 0dminishrakion od aingls dos d Kr dug


    max1ncya asL wih inrtast dose
    in dose

    inrROs in abaorpHon Hal


    ExprAAARd in g/m or mg/
    mg/m
    ml

    A ttmax Himtptak plasma Conunrahon)


    maxl! to achizve
    ugurad puok plaama tamuntrahon
    qives an inditahon d
    Hate of absorphon
    Expessd ih minut' or houts.
    da craasu as as d absotpion incvass

    i) AUC (Auo unday K plasma Jaul-himt unve)


    9/ves a muasuTL oKe extent of abtorphon or
    omount orug that achs hi systemic cirulahon.

    MTC
    DuraHon d acHon

    Croox Thnapauic
    Range

    MEC

    AUC

    onset
    tme mox
    Mulhbl_Do_Study r . Parjanya Shukla
    &
    x Drug administ Tad or a lhat 5 biologieal Dr. M.P. Singh Class
    halfves toih a doBing intava lGual to or
    qTiater han Ka biologYeal Kalf i f to uach
    Atudy sfate
    blood Aambl should b» takan a end oavions i
    dosing intva 8to lo Aampls o t h
    admnistraHon nux dosa.
    DoR DoA! DoA DOA DOA&
    T T t

    Css, mox
    Steady-stab Javal
    Cs5, min

    AUC foT ont


    dosing intanvad
    a Ataady -Atabe.

    TK axten d bicovailablity ton br delaymind by


    by
    for Singl dona sbady tor mulkplu dost stucdly-

    F AUCr Div F 9UCs Du4 Thn


    u [AUC)i. Doral AUCd. Dtnt std
    f AUGa DAtu. f1om prak-plasmo Cont dsady
    AUC) td. Dtat stads Css. max
    FyCs.mos)atDgu T4st
    CCss, max)std. Dtmt Tsd.
    (UrinaryExTonStudios Dr. Parjanya Shukla

    Basd on K prinu bl a &


    Dr. M. P. Singh Classes

    th urinoy excrukion ounchongad drug i divuchl


    ropor honal to K plama Conunrahon d drug

    x DetayminaHon obroavailabil'ty wing urinary exCe Hon Ahould be


    COnduchad only if a east 20% d odministarad dose dosR is
    RXeYAtad
    unchanged in hi urint
    TR Akudy ia wafw for
    ODrugs 2xtenaivly excYated unchanged in urins
    rtain ia3ids, diurahits and ALuphona midus .

    0
    Drugs hat hava urint a R aits oacHon -

    Uvinavy aniAaphics, nitrofanantoin, Koxaminu.

    noninvasiv mahod ,Ao buHar þakiant complianu.

    Mphod- (olldion ourin a ogular inkunvalsOT a tim apon


    qual to 7 biologicas Ralfbivs.

    Analyais dunthangad drug in rollacad Aomble


    ThYLA important poramatas in uine exrzhion data for Aingle
    Thru
    do study By-Dr. Mahundro Pralhb SingA
    ) (dX/d4)max Maximum uyinary exerahHon uabe
    obtainud rom tk piak d plol b/w Aal d
    RxCTa Hon VTAUS midpolnt im od urin to.lutton
    puriod.
    *d valu incrsasB a Hak ond 2xtant d obaorphion
    Imcrases.
    i) (tu) may imt or maximum oxcyahon xaha)
    Shukla
    analoqous to max o laumo JavaJ dala. Dr.Parjangya
    Dr. M. P. Singh Classe

    dts valu darzasts a th abio7phon xaBs in(TOASS.

    ) X ( (umadahu amaunt d drug axcrated in Ki unine)


    4 ulakad to AUC oploima dausl da

    inriases as hi xtent d absophon incraanes.

    (dxu/dt) max

    (tu mo
    midpoint Hm o Urin (olluchion period.

    T xent d bicavailabiliky ik calawalad


    or Sing doar afud muuli dops bfudy to staady State

    F Xu)oral Div.
    (Xu)iv Doa (Xu,ss)pt Datd.Tast
    F(Xu,s)
    Bd.
    Dtust TsBd.
    (X)1 Datd.
    (X) shd. Dta Wheu Xu, ss is Ko amount o drug
    exCYoted unchongad duuing a
    By-Dr.0Mohundo Prakop Singh singl do ntarval ostaody-stoke

    You might also like

    pFad - Phonifier reborn

    Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

    Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


    Alternative Proxies:

    Alternative Proxy

    pFad Proxy

    pFad v3 Proxy

    pFad v4 Proxy